NeuroSense Therapeutics Ltd. Stock price
Equities
NRSN
IL0011809592
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.82 USD | +5.20% | +0.55% | +131.85% |
Feb. 21 | Neurosense Therapeutics Ltd. Reports Additional Positive Results from Its ALS Phase 2B Paradigm Trial | CI |
Dec. 28 | NeuroSense Gets Non-Compliance Notice From Nasdaq | MT |
Financials (USD)
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 24.87M |
---|---|---|---|---|---|
Net income 2023 * | -11M | Net income 2024 * | -14M | EV / Sales 2023 * | - |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-2.22
x | P/E ratio 2024 * |
-2.21
x | Employees | 14 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 67.34% |
1 day | +5.20% | ||
1 week | +0.55% | ||
Current month | +2.82% | ||
1 month | +1.11% | ||
3 months | +133.33% | ||
6 months | +142.67% | ||
Current year | +131.85% |
Managers | Title | Age | Since |
---|---|---|---|
Alon Ben-Noon
FOU | Founder | 45 | 17-02-12 |
Or Eisenberg
DFI | Director of Finance/CFO | 42 | 21-05-31 |
Yael Barak
CMP | Compliance Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 21-12-20 | |
Chairman | 67 | 21-09-30 | |
Cary Claiborne
BRD | Director/Board Member | 64 | 21-11-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1.82 | +5.20% | 113,890 |
24-03-27 | 1.73 | +1.76% | 82,381 |
24-03-26 | 1.7 | -6.59% | 133,816 |
24-03-25 | 1.82 | +3.41% | 56,461 |
24-03-22 | 1.76 | -2.76% | 184,142 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+131.85% | 24.87M | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |